Selatinib structure
|
Common Name | Selatinib | ||
---|---|---|---|---|
CAS Number | 1275595-86-2 | Molecular Weight | 565.06 | |
Density | 1.4±0.1 g/cm3 | Boiling Point | 740.5±60.0 °C at 760 mmHg | |
Molecular Formula | C29H26ClFN4O3S | Melting Point | N/A | |
MSDS | N/A | Flash Point | 401.6±32.9 °C |
Use of SelatinibSelatinib is a reversible and orally active dual EGFR and ErbB2 inhibitor with IC50s of 13 nM and 22.5 nM, respectively. Selatinib has anticancer effects[1]. |
Name | SELATINIB |
---|---|
Synonym | More Synonyms |
Description | Selatinib is a reversible and orally active dual EGFR and ErbB2 inhibitor with IC50s of 13 nM and 22.5 nM, respectively. Selatinib has anticancer effects[1]. |
---|---|
Related Catalog | |
Target |
EGFR:13 nM (IC50) ErbB2:22.5 nM (IC50) |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 740.5±60.0 °C at 760 mmHg |
Molecular Formula | C29H26ClFN4O3S |
Molecular Weight | 565.06 |
Flash Point | 401.6±32.9 °C |
Exact Mass | 564.139832 |
LogP | 4.81 |
Vapour Pressure | 0.0±2.4 mmHg at 25°C |
Index of Refraction | 1.676 |
4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfinyl)ethyl]amino]methyl]-2-furanyl]- |
6TLR8U8O3C |
N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfinyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine |
SELATINIB |
UNII:6TLR8U8O3C |